Balance Sheet: Liabilities and Stockholders’ Equity
Quarterly Data

Beginner level

The balance sheet provides creditors, investors, and analysts with information on company’s resources (assets) and its sources of capital (its equity and liabilities). It normally also provides information about the future earnings capacity of a company’s assets as well as an indication of cash flows that may come from receivables and inventories.

Liabilities represents obligations of a company arising from past events, the settlement of which is expected to result in an outflow of economic benefits from the entity.

Thermo Fisher Scientific Inc., consolidated balance sheet: liabilities and stockholders’ equity (quarterly data)

US$ in millions

	Jun 27, 2020	Mar 28, 2020	Dec 31, 2019	Sep 28, 2019	Jun 29, 2019	Mar 30, 2019	Dec 31, 2018	Sep 29, 2018	Jun 30, 2018	Mar 31, 2018	Dec 31, 2017	Sep 30, 2017	Jul 1, 2017	Apr 1, 2017	Dec 31, 2016	Oct 1, 2016	Jul 2, 2016	Apr 2, 2016	Dec 31, 2015	Sep 26, 2015	Jun 27, 2015	Mar 28, 2015
Short-term obligations and current maturities of long-term obligations	675	738	676	661	2,377	1,336	1,271	1,014	1,711	2,814	2,135	2,762	1,540	1,882	1,256	1,972	2,516	3,383	1,053	3,034	3,360	4,161
Accounts payable	1,385	1,599	1,920	1,659	1,391	1,462	1,615	1,344	1,359	1,354	1,428	1,124	982	1,031	926	942	847	853	822	783	819	828
Accrued payroll and employee benefits	1,184	755	1,010	883	809	704	982	817	755	643	918	771	613	521	709	611	522	421	598	549	479	487
Contract liabilities	975	938	916	943	1,062	967	809	797	816	909	—	—	—	—	—	—	—	—	—	—	—	—
Deferred revenue	—	—	—	—	—	—	—	—	—	—	719	747	542	539	486	492	359	361	318	321	334	333
Other accrued expenses	1,794	1,470	1,675	1,698	1,870	1,429	1,470	1,224	1,339	1,352	1,848	1,627	1,399	1,330	1,490	1,243	1,286	1,305	1,356	1,048	1,109	1,053
Current liabilities	6,013	5,500	6,197	5,844	7,509	5,898	6,147	5,196	5,980	7,072	7,048	7,031	5,076	5,303	4,866	5,260	5,528	6,323	4,147	5,735	6,100	6,861
Deferred income taxes	1,750	2,137	2,192	2,001	1,936	2,145	2,265	2,550	2,599	2,606	2,766	3,135	2,320	2,463	2,557	2,715	2,482	2,694	2,623	3,032	3,135	3,223
Other long-term liabilities	3,317	3,261	3,241	3,137	3,133	3,048	2,515	2,682	2,670	2,657	2,569	1,887	1,470	1,464	1,573	1,437	1,348	1,359	1,295	1,252	1,196	1,162
Long-term obligations, excluding current maturities	20,638	19,231	17,076	16,392	16,663	16,812	17,719	17,760	17,709	18,122	18,873	19,230	15,256	15,188	15,372	16,940	11,632	11,653	11,474	10,278	10,664	10,696
Long-term liabilities	25,705	24,629	22,509	21,530	21,732	22,005	22,499	22,992	22,978	23,385	24,208	24,252	19,046	19,116	19,502	21,092	15,461	15,706	15,392	14,562	14,994	15,082
Total liabilities	31,718	30,129	28,706	27,374	29,241	27,903	28,646	28,188	28,958	30,457	31,256	31,284	24,122	24,418	24,368	26,352	20,990	22,028	19,539	20,297	21,095	21,943
Preferred stock, $100 par value; none issued	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Common stock, $1 par value	436	435	434	434	433	433	432	431	430	429	428	428	417	416	415	415	414	413	412	411	411	410
Capital in excess of par value	15,334	15,186	15,064	14,964	14,887	14,771	14,621	14,526	14,408	14,319	14,177	14,112	12,328	12,252	12,140	12,097	12,017	11,919	11,801	11,733	11,669	11,607
Retained earnings	23,860	22,791	22,092	21,165	20,482	19,439	18,696	17,866	17,226	16,542	15,914	15,446	14,972	14,419	13,927	13,357	12,943	12,485	12,142	11,600	11,184	10,732
Treasury stock at cost	(6,766)	(6,765)	(5,236)	(4,486)	(4,443)	(4,441)	(3,665)	(3,414)	(3,128)	(3,125)	(3,103)	(3,101)	(3,070)	(2,819)	(2,306)	(2,055)	(2,027)	(2,026)	(1,008)	(1,007)	(989)	(988)
Accumulated other comprehensive items	(2,989)	(3,088)	(2,679)	(2,722)	(2,630)	(2,509)	(2,498)	(2,519)	(2,491)	(2,042)	(2,003)	(2,183)	(2,256)	(2,474)	(2,636)	(2,155)	(2,082)	(1,867)	(1,997)	(1,886)	(1,595)	(1,847)
Shareholders’ equity	29,875	28,559	29,675	29,355	28,729	27,693	27,586	26,890	26,445	26,123	25,413	24,702	22,392	21,795	21,539	21,659	21,264	20,924	21,350	20,850	20,680	19,915
Total liabilities and shareholders’ equity	61,593	58,688	58,381	56,729	57,970	55,596	56,232	55,078	55,403	56,580	56,669	55,985	46,514	46,214	45,908	48,011	42,253	42,953	40,889	41,147	41,774	41,857

Balance sheet item	Description	The company
Current liabilities	Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.	Thermo Fisher Scientific Inc.’s current liabilities decreased from Q4 2019 to Q1 2020 but then increased from Q1 2020 to Q2 2020 not reaching Q4 2019 level.
Long-term liabilities	Amount of obligation due after one year or beyond the normal operating cycle, if longer.	Thermo Fisher Scientific Inc.’s long-term liabilities increased from Q4 2019 to Q1 2020 and from Q1 2020 to Q2 2020.
Total liabilities	Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.	Thermo Fisher Scientific Inc.’s total liabilities increased from Q4 2019 to Q1 2020 and from Q1 2020 to Q2 2020.
Shareholders’ equity	Total of all stockholders’ equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity’s stockholders’ equity attributable to the parent excludes the amount of stockholders’ equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.	Thermo Fisher Scientific Inc.’s shareholders’ equity decreased from Q4 2019 to Q1 2020 but then increased from Q1 2020 to Q2 2020 exceeding Q4 2019 level.

Thermo Fisher Scientific Inc. (NYSE:TMO)

Balance Sheet: Liabilities and Stockholders’ EquityQuarterly Data

Balance Sheet: Liabilities and Stockholders’ Equity
Quarterly Data